
|Articles|February 24, 2010
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Safety Considerations in Retinal Vascular Diseases
5






















